Estrogen receptor alpha gene polymorphisms and risk of HBV-related acute liver failure in the Chinese population by Zehui Yan et al.
Yan et al. BMC Medical Genetics 2012, 13:49
http://www.biomedcentral.com/1471-2350/13/49RESEARCH ARTICLE Open AccessEstrogen receptor alpha gene polymorphisms
and risk of HBV-related acute liver failure in the
Chinese population
Zehui Yan1, Wenting Tan1, Yunjie Dan1, Wenli Zhao1, Chunqing Deng1, Yuming Wang1* and Guohong Deng1,2*Abstract
Background: The sexual dimorphism of hepatitis B virus (HBV) -related liver diseases is related with estrogen and
its receptors. Recent reports indicate that abnormal expression of estrogen receptor alpha (ESR1) may be a hallmark
for the progression of liver disease and HBV carriers presenting variant ESR1 have an extremely aggressive clinical
course. Here we examine whether the ESR1 polymorphisms or its haplotypes are related to HBV-related acute liver
failure (ALF) risk among chronic HBV carriers in a Chinese population.
Methods: A total of 1216 unrelated Han Chinese HBV carriers were recruited in this hospital-based case–control
study, including 359 HBV surface antigen (HBsAg) carriers affected with ALF and 857 asymptomatic HBsAg carriers.
Two ESR1 haplotype tagging polymorphisms, c.30 T>C (rs2077647) and c.453-397 T>C (rs2234693), were
genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay.
Results: We observed a significantly increased susceptibility to HBV-ALF associated with the c.30 C allele
(P = 8.65 × 10-4), c.453-397 C allele (5.37 × 10-4) and [c.30 C; c.453-397 C] haplotype (Dominant model, P =0.0004,
odds ratio = 1.53, 95% CI 1.23 ~ 1.96) compared with the T alleles and [c.30 T; c.453-397 T] haplotype of c.30 T> C
and c.453-397 T> C polymorphisms, respectively.
Conclusions: Our study suggests that [c.30 C; c.453-397 C] hapotype may be a risk factor for genetic susceptibility
to HBV-related ALF in the Chinese population. It also emphasizes the importance of ESR1 in the pathophysiology of
HBV-related ALF on the population level.Background
Acute liver failure (ALF) is a condition in which rapid
deterioration of liver function results in altered menta-
tion and coagulopathy in previously normal individuals.
The most widely accepted definition of ALF includes
evidence of coagulation abnormality, usually an INR ≥
1.5, and any degree of mental alteration (encephalop-
athy) in a patient without preexisting cirrhosis and with
an illness of <26 weeks duration [1]. ALF is the final
common pathway of severe hepatocyte injury. The eti-
ology of ALF shows worldwide variation, prominent
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Unlike western countries, ALF is one of the end-staged
liver diseases caused mainly by hepatitis B virus (HBV)
infection (at least 60%) in China [2]. However, regardless
of etiology, chronic hepatitis B progresses at unequal
rates between males and females, being more frequent
in men than in women [3]. This sexual dimorphism and
the greater progression to the end-staged liver diseases
in men and postmenopausal women may be due, at least
in part, to lower production of estrogen and a reduced
response to the action of estrogen [4].
Estrogen is a potent endogenous antioxidant which
attenuates induction of redox sensitive transcription fac-
tors and hepatocyte apoptosis by inhibiting generation of
reactive oxygen species [5]. The effects of estrogens are
mediated by estrogen receptors (ESRs). When estrogen
binds to its receptor, it would activate and regulate. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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oma 2, nuclear factor κB, tumor necrosis factor α and
interleukin-6 [6-8]. There are two known ESRs: estrogen
receptor α (ESR1) and estrogen receptor β (ESR2). The
majority of the biological effects of estrogen are
mediated by ESR1 in the liver [9]. ESR1 has been well
characterized in human liver [10], hepatic cytosolic
ESR1 content was detected on the progression of
chronic liver disease [11-13]. The abnormal ESR1
expressions in the liver have been implicated in stimulat-
ing hepatocyte injury and may act as liver disease indu-
cers or promoters [14]. Furthermore, variant ESR1 is
expressed to a greater extent in male patients than in
females, even at an early stage of chronic liver disease
[15,16]. Therefore, variant ESR1 may be a hallmark for
the progression of liver disease and HBV carriers pre-
senting variant ESRa1 have an extremely aggressive clin-
ical course [17].
Investigators have also hypothesized the ESR1
(NM_000125.3) genetic variants may influence an indivi-
dual's estrogen-sensitive phenotypes [18]. We have
screened single nucleotide polymorphisms (SNPs) system-
atically in the ESR1 gene and two linkage disequilibrium
(LD) blocks covering the ESR1 gene were identified [19].
Two polymorphisms, ESR1 c.30 T>C (rs2077647, previ-
ously reported T29C, exon 1) and c.453-397 T>C
(rs2234693, previously reported IVS1 T-401 C, intron 1),
which were identified as haplotype tagging SNPs, influ-
ence the susceptibility to persistent HBV infection [19],
HBV-related liver cirrhosis [20] and hepatocellular
carcinoma [21]. We also observed that the relative mRNA
levels of the risk c.30 C allele were consistently higher
than those of the c.30 T allele in c.30 T>C heterozygotes
[21]. Functional analyses also showed that the c.453-397 T
>C polymorphism is a novel c.453-397 C allele-specific
and c-myb-dependent enhancer-like cis-acting regulatory
variation and could be part of the genetic variations
underlying the susceptibility of individuals to HBV-related
diseases [20].
Host genetic polymorphisms may involve the the
pathophysiology of HBV-ALF. We have reported that
the -592 C allele and the -1082A-819 C-592 C haplotype
in the IL-10 gene promoter were associated with an
increased susceptibility to ALF in HBV carriers [22]. In
this study, we hypotheses that ESR1 may be another
appropriated biological candidate susceptibility gene for
HBV-ALF. It is expected that the ESR1 genetic variation
could influence the effects of estrogens, which in turn
results in genotype-dependent differences in risk of
HBV-ALF. Therefore, we selected the two haplotype tag-
ging SNPs (c.30 T>C and c.453-397 T>C) from previ-
ously association LD block of ESR1 and examined their
relationships with the susceptibility to HBV-ALF in a
large sample of case–control cohort.Methods
Study participants
Hospital-based case–control study was conducted at
Southwest Hospital (Chongqing, China) between February
2001 and December 2009. A total of 1216 unrelated Han
Chinese HBV carriers were recruited, including 359 HBV
surface antigen (HBsAg) carriers affected with ALF and
857 asymptomatic HBsAg carriers. All HBsAg carriers
were positive for both HBsAg and antibody to HBV core
antigen (anti-HBc) of the IgG type for at least 12 months.
All carriers were measured with liver function tests,
serum immunologic marker screening, at least one liver
image examination (Ultrasonography, Computed Tomog-
raphy, Magnetic Resonance Imaging and Fibroscan), and
113 (9.3%) were examined with histological biopsy. All
carriers had no serologic evidence for coinfection or
superinfection with hepatitis A virus, hepatitis C virus,
hepatitis D virus, hepatitis E virus, and human immuno-
deficiency virus.
ALF was defined as liver failure with jaundice, coagu-
lation abnormality (usually an INR ≥1.5), and any degree
of mental alteration (encephalopathy) in a patient with
an illness of less than 26 weeks duration. All patients
with ALF had no evidence with preexisting cirrhosis. In-
formation on acetaminophen and idiosyncratic drug and
treatment history of these patients was obtained mainly
from clinical records and short telephone interviews
when necessary. The carriers, who had history of acet-
aminophen overdose and idiosyncratic drug reactions,
were excluded from the HBV-ALF group. Asymptomatic
HBV carriers were diagnosed according to the following
criteria: (1) lack of any clinical symptoms; (2) normal
liver enzyme tests; (3) normal peripheral blood leucocyte
(4 ~ 10 × 109/L) and platelet (100 ~ 400 × 109/L) counts;
(4) serum albumin >39 g/L, globulin <35 g/L, and the
ratio of albumin to globulin (A/G) >1.5; (5) normal pro-
thrombin time and serum total bilirubin; (6) no abnor-
mal findings on abdominal ultrasound scans; (7) no
esophageal varix revealed by electronic gastroscopy. The
examininations or tests were performed once every
6 months from February 2001 to December 2007. The
carriers, who occurred to the hepatitis symptoms or cir-
rhosis evidences during the follow-up, were also
excluded from the ASC group.
Further clinical and demographic characteristics of the
studied population are shown in Table 1. All subjects
provided informed consent to participate in the study, as
approved by the ethical committee of Southwest Hos-
pital, Chongqing, China.
DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood leu-
kocytes from 5 mL whole blood by using standard phe-
nol/chloroform protocols. DNA samples were diluted
Table 1 Distribution of Selected Characteristics and ESR1
Polymorphisms in Participants
Characteristic ASC HBV-ALF P value
(n =857) (n=359)
Gender, no. (%)
Men 510 (59.5) 298 (83.0)
Women 347 (40.5) 61(17.0) <0.001
Age (years), mean (SD) 36.6 ± 11.3 41.1 ± 12.7 <0.001
Alcohol drinkers, no. (%) 160(18.7) 121 (33.7) <0.001
HBeAg positive, no (%) 298(34.8) 107(29.8) 0.094
TBil (μmol/L) 13.4 ± 4.3 321.1 ± 166.1
ALT (IU/L) 27.9 ± 10.7 410.1 ± 541.6
c.453-397 T>C (rs2234693)
TT, no. (%) 330(38.4) 109(30.4)
TC, no. (%) 424(49.6) 182(50.7)
CC, no. (%) 103(12.0) 68(18.9)
T allele, no. (%) 1086(62.4) 400 (55.7)
C allele, no. (%) 632(36.9) 318 (44.3) 5.37 × 10-4
c.30 T>C (rs2077647)
TT, no. (%) 418(48.8) 143 (39.8)
TC, no. (%) 348(40.6) 160 (44.7)
CC, no. (%) 91 (10.6) 56 (15.6)
T allele, no. (%) 1184(69.1) 446 (62.1)
C allele, no. (%) 530 (30.9) 272 (37.9) 8.65 × 10-4
Notes: “Drinker” was defined as alcohol consumption of ≥40 g/week for men
and ≥20 g/week for women, which included occasional drinkers and daily
drinkers. The genotype distributions of SNPs in each group were in Hardy–
Weinberg equilibrium. P values were given for the comparison between ASC
and HBV-ALF groups by χ2 tests. TBil, total bilirubin; ASC, asymptomatic HBV
carriers; HBV-ALF, patients with HBV-related acute liver failure.
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panels), with 94 samples and 2 controls (DNA-free
water) in each plate. Entrez nucleotide database (http//
ncbi.nlm.nih.gov) NT_025741.15:g and dbSNP ID were
used as the reference sequences for ESR1 genomic and
cDNA sequences. DNA sequence variations are named
according to the nomenclature recommendations from
http://www.hgvs.org/mutnomen/recs-DNA.html [23,24].
The ESR1 c.30 T>C and c.453-397 T>C polymorph-
isms were genotyped by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP)
analysis in our case–control population.
For the c.30 T>C polymorphism, an amplification
using the forward primer 5’-GACCATGACCCTCCA
CACCAAAGGATC -3(G, mismatch base) and reverse
primer 5’- ACCGTAGACCTGCGCGTTG -3’ was per-
formed at an annealing temperature of 61 °C. The reac-
tion yielded a 220 bp amplicon. A BamH I recognition
site was introduced by 1-base mismatch (underlined
base) in the forward primer. Three microliters PCR pro-
ducts were digested with 4U BamH I (Toyobo, Japan).
Digested amplicons from the homozygotes for c.30 Callele appeared as 197-bp and 23-bp bands on the agar-
ose gel electrophoresis, while homozygotes for c.30 T al-
lele appeared as a 220-bp band. Heterozygotes of c.30TC
had all 3 of these bands.
For the c.453-397 T>C polymorphism, amplification
using the forward primer 5’-CATGAACCACCATGCT
CAGTC-3’ and reverse primer 5’-ACTCTCTGGGA
GATGCAGCAG-3’ was performed at an annealing
temperature of 63 °C. The reaction yielded a 548 bp
amplicon. Three microliters PCR products were digested
with 4U PvuII (Toyobo, Japan), and separated on 3%
agarose gel and stained with ethidium bromide for
visualization under UV light. Digested amplicons from
the homozygotes for c.453-397 T allele appeared as 346-
bp and 202-bp bands on the agarose gel electrophoresis,
while homozygotes for c.453-397 C allele appeared as a
548-bp band. Heterozygotes of c.453-397TC had all 3 of
these bands.
Genotyping was performed in a blind manner without
information of subjects’ case/control status. The accur-
acy of genotyping data for SNP obtained from PCR-
RFLP was validated by direct sequencing of 90 masked,
random samples of patients.
Haplotype construction and statistical analysis
Allele frequencies for each SNP were determined by
gene counting, and the significance of deviations from
Hardy-Weinberg equilibrium was tested using the
random-permutation procedure implemented in the
Arlequin package (http://lgb.unige.ch/arlequin/). ESR1
haplotypes were assigned by the PHASE program [25].
Pair-wise linkage disequilibrium (LD) between SNPs was
analyzed by LDA [26].
Statistical analysis was performed using SPSS software
(version 9.0; SPSS Inc, Chicago, IL). A p-value less than
0.05 was considered significant. χ2 tests were performed
to examine the differences in the allele frequency and
genotype distribution between groups. Multivariable lo-
gistic regression analysis was performed to adjust risk
factors such as age, sex, and alcohol use. The association
between genotyped polymorphisms and the risk of dis-
ease was estimated by P values, odds ratios (ORs), and
95% confidence intervals (95% CIs).
Results
The selected characteristics and genotype distributions
of the ESR1 c.30 T>C and c.453-397 T>C poly-
morphisms in ASCs and HBV-ALF groups are summar-
ized in Table 1. Although efforts were made to obtain
good matches on age and sex between ASCs and HBV-
ALF groups, HBV-ALF groups were older and consisted
more men (P< 0.001). The difference in the alcohol
consumption status between the ASCs and HBV-ALF
groups (P< 0.001) was observed,which may due to
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There was no significant difference with the percentage
of HBeAg positive (P =0.094) between the asymptom-
atic HBV carriers (34.8%) and the patients of HBV-
related ALF (29.8%). The genotype distributions for the
two SNPs were in Hardy–Weinberg equilibrium in each
group. The c.30 T>C and c.453-397 T>C polymorph-
isms were in linkage disequilibrium with each other
(D' = 0.796, r2 = 0.538, Q value = 0.951). The c.30 C and
c.453-39 C allele frequencies were significantly higher
in HBV-ALF patients than those in ASCs (P< 0.05).
Subjects bearing at least one c.453-39 C and c.30 C
alleles had an increased susceptibility to HBV-related
ALF compared with those without c.453-39 C and
c.30 C alleles (c.453-397 T>C, P= 5.37 × 10-4; T29C,
P =8.65 × 10-4) in our case–control sample.
To decrease the bias of age and sex on the effect esti-
mates, we conducted stratification analysis for age and
sex in total 1216 case and control individuals (Table 2).
The association between two haplotype tagging SNPsTable 2 Stratification Analysis of Age and Gender on Associat
and Different Groups
c.453-397 T>C
AsC HBV-ALF P value OR (95%
Men only. n = 510 n= 298
TT 193(37.8) 94(31.5)
TC 263(51.6) 149(50.0)
CC 54(10.6) 55(18.5) 0.003 1.39(1.12-
T allele 649(63.6) 337(56.5)
C allele 371(36.4) 259(43.5) 0.005
Women only n = 347 n= 61
TT 137(39.5) 15(24.6)
TC 161(46.4) 33(54.1)
CC 49(14.1) 13(21.3) 0.022 1.56(1.08-
T allele 435(62.7) 63(51.6)
C allele 259(37.3) 59(48.4) 0.021
Age≥ 40 y n = 277 n= 166
TT 118(42.6) 54(32.5)
TC 135(48.7) 83(50.0)
CC 24(8.7) 29(17.5) 0.008 1.83(1.21-
T allele 371(67.0) 191(57.5)
C allele 183(33.0) 141(42.5) 0.005
Age< 40 y n = 580 n= 193
TT 212(36.6) 55(28.5)
TC 289(49.8) 99(51.3)
CC 79(13.6) 39(20.2) 0.036 1.35(1.09-
T allele 713(61.5) 209(54.1)
C allele 447(38.5) 177(45.9) 0.011
Notes: P values were given for the comparison of the allele effect between ASC an
interval (95%CI) were given for the comparison of the genotype effect between AS
covariates, including age, sex, HBeAg status and alcohol consumption. ASC, asympt(c.30 T>C and c.453-397 T>C) and HBV-ALF
remained significant in male patients (c.453-397 T>C,
P =0.005; c.30 T>C, P= 0.022), female patients(c.453-
397 T>C, P= 0.033; c.30 T>C, P= 0.021), patients with
age ≥ 40 years (c.453-397 T>C, P =0.005; c.30 T>C,
P= 0.0003), and patients with age< 40 years (c.453-
397 T>C, P= 0.011; c.30 T>C, P =0.003). As table 2
showed, the logistic regression analysis with adjustment
for covariates, including age, sex, HBeAg status and al-
cohol consumption also suggested that the genotype
effects of these two SNPs were significantly associated
with the risk to HBV-ALF in both gender and patients
at any age (with an age ≥ 40 years or< 40 years).
Haplotypes based on the c.30 T>C and c.453-397 T>
C polymorphisms were constructed to derive haplotypes
specifically correlated with HBV-ALF. Four haplotypes,
[T; T], [T; C], [C; T], and [C; C], were observed, and two
haplotypes, [T; T] and [C; C], had frequencies more than
10%. The estimated haplotype distribution differed
significantly between the ASCs and HBV-ALF groupsion between ESR1 c.30 T>C & c.453-397 T>C Genotypes
c.30 T>C
CI) AsC HBV-ALF P value OR (95%CI)
n= 510 n= 298
233(457) 121(40.6)
230(45.1) 131(43.9)
1.73) 47(9.2) 46(15.4) 0.026 1.47(1.06-2.17)
696(68.2) 373(62.6)
324(31.8) 223(37.4) 0.022
n = 347 n= 61
185(53.3) 22(36.1)
118(34.0) 29(47.5)
2.35) 44(12.7) 10(16.4) 0.037 1.63(1.07-2.47)
488(70.3) 73(59.8)
206(29.7) 49(40.2) 0.021
n = 277 n= 166
151(54.5) 71(42.8)
101(36.5) 74(44.6)
2.63) 25(9.02) 21(12.7) 0.041 1.62(1.08-2.54)
403(72.7) 216(65.1)
151(27.3) 116(34.9) 0.0003
n= 580 n= 193
267(46.0) 72(37.3)
247(42.6) 86(44.6)
2.21) 66(11.4) 35(18.1) 0.024 1.54(1.07-1.98)
781(68.2) 230(59.6)
369(31.8) 156(40.4) 0.003
d HBV-ALF groups by χ2 tests. Odds ratios (OR) and their 95% confidence
C and HBV-ALF groups by logistic regression analysis with adjustment for
omatic HBV carriers; HBV- ALF, patients with HBV-related acute liver failure.
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haplotype decreased significantly in the HBV-ALF group,
as compared to ASCs. We categorized the ESR1 haplo-
types into three groups, i.e., ‘[T; T]/[T; T]’ homozygotes,
‘[T; T]]/[-,-]’ heterozygotes, and ‘[-;-]/[-;-]’ homozygotes
(‘[-;-]’means non-[T; T] haplotypes, Table 3). Logistic re-
gression analysis with adjustment for age, sex, HBeAg
status and alcohol consumption indicated significant dif-
ferences in the distribution of the three haplotype groups
between the ASC and HBV-ALF groups. Non-[T; T]]
(‘[-;-]/[-;-]’) haplotypes had a significantly increased risk
to HBV-ALF (Dominant model, P= 0.0004, odds ratio =
1.53, 95% CI 1.23 ~ 1.96).Discussion
In our case–control association study, we observed an
increased risk of HBV-ALF in patients who carry ESR1
c.30 C, c.453-397 C allele and [c.30 C; c.453-397 C]
haplotype. This risk estimates did not change after ad-
justment for gender, age and alcohol consumption status,
indicated that ESR1 c.30 C, c.453-397 C allele and
[c.30 C; c.453-397 C] haplotype is an independent risk
factor. Combined with the novel evidences that the
c.453-397 T>C polymorphism is a novel c.453-397 C
allele-specific and c-myb-dependent enhancer-like cis-
acting regulatory variation [20], our study emphasizes
the importance of ESR1 in the pathophysiology of HBV-
ALF on the population level. To our knowledge, this is
the first report that the functional polymorphisms of
ESR1gene may determine an individual’s susceptibility to
HBV-ALF.
The design and results of our study manifest the fea-
tures that are considered desirable components of an
ideal association study [27]. These characteristics includeTable 3 Results of the Association Test for ESR1
Haplotypes between ASC and HBV-related ALF Groups
Characteristic AsC HBV-ALF P value OR (95%CI)
(2n= 1714) (2n= 690)
Haplotype, no. (%)
[T; T] 1023(59.7) 365(50.8)
[T; C] 142(8.3) 82(11.5)
[C; T] 54(3.1) 36(5.0)
[C; C] 495(28.9) 235(32.7)
Total (3df) } 0.0002
Haplotype groups, no. (%)
[T; T]/[T; T] 294(34.3) 97(27.1)
[T; T]/[-;-] 435(50.8) 171(47.6)
[-;-]/[-;-] 128(14.9) 91(25.3) 0.0004 1.53(1.23 ~ 1.96)
Notes: }For haplotype, P values were given by 2 × 4 table chi-square; ‘[-;-]’
means any other haplotypes; OR=odds ratio; CI= confidence interval; the
association was analyzed by logistic regression analysis with adjustment for
covariates, including age, sex, and alcohol consumption. AsC, asymptomatic
carriers;HBV- ALF, patients with HBV-related acute liver failure.a large cohort size, rigorous phenotypic selection, inde-
pendent sample validation, plausible biological context,
low P values, and appropriate statistical and LD test.
Most HBV carriers are infected by maternal-infantile
transmission in China. Both ALF cases and controls are
HBV carriers in this study, which ensure all the subjects
in the study having the history of HBV exposure, the as-
sociation of ESR1 polymorphisms with ALF may not due
to population bias. To decrease the bias of age and sex
on the effect of the estimate, we conducted stratification
analysis for age and sex. Interestingly the association be-
tween the two ESR1 polymorphisms (c.453-397 T>C
and c.30 T>C) and HBV-ALF remained significant in
both sex and patients at any age (with an age ≥ 40 years
or< 40 years). The P value for the whole case control
comparison is at the 10-4 level. According to the Better
Associations for Disease and Genes (BADGE) system for
describing genetic associations proposed by Manly [28]
and the criteria proposed by Wacholder et al. [29], the
false positive report probability (FPRP) of our results is
very low. Although the highly significant association be-
tween ESR1 polymorphisms and susceptibility to HBV-
related ALF derives from biologically based a priori
hypothesis, our initial findings should be independently
verified in populations of different ancestry, especially in
other East Asia populations, where HBV infection is the
major cause of ALF. Furthermore, it is reasonable to
speculate that the effects of the two SNPs on the occur-
rence of ALF may be different between postmenopausal
and premenopausal women. Then, it will be better to
conduct a stratification analysis for menopausal status in
total HBV-ALF women. However, the number of poten-
tial postmenopausal women (N= 27) and premenopausal
women (N= 34) in the HBV-ALF group is too small to
gain enough statistical. In the following study, the
expanded numbers of women patients with HBV-ALF
will be help clarify the effects of the two SNPs on the oc-
currence of ALF between postmenopausal and premeno-
pausal women.
It is conceivable that the common sequence variations
in the ESR1 gene affect the risk of different disease
phenotype, such as breast cancer [30,31], osteoarthritis
[32], cardiovascular disease [33], and migraine [34]. Our
study group also has found that the ESR1 polymorph-
isms influenced the susceptibility to persistent HBV in-
fection [19], HBV-related liver cirrhosis [20] and
hepatocellular carcinoma [21] and showed that the
c.453-397 T>C polymorphism is a novel c.453-397 C
allele-specific and c-myb-dependent enhancer-like cis-
acting regulatory variation and could be part of the gen-
etic variations underlying the susceptibility of individuals
to HBV-related diseases [20]. The consistency of func-
tional consequences is an additional strong point of our
genetic epidemiological investigation.
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esis of HBV-related liver diseases [17,35]. During the
course of chronic hepatitis B progressing to end-stage liver
disease, variant forms of ESR1 predominates and some-
times becomes the only form expressed [17]. This variant
lacks the estrogen-binding domain, but the intact DNA-
binding domain maintains constitutive transcriptional ac-
tivity, plays an important roles in the modulation of cell
proliferation and inflammatory processes [36,37]. HBV
carriers presenting variant ESR1 have an extremely ag-
gressive clinical course.[13,17] Since variant ESR1 isoform
predominates and sometimes becomes the only form
expressed in the liver with endstage liver diseases, variant
forms of ESR1 may be one of the possible mechanisms
underlying the fact that c.453-397 T>C genetic variation
influences susceptibility to HBV-ALF. our results, that the
disease susceptible ESR1 c.453-397 C allele had much
stronger transcription activity than c.453-397 T allele,
might suggest the liver failure risked c.453-397 C allele
amplifies ESR1 transcription and probably produces more
variant ESR1 isoforms compared with c.453-397 T allele.
Then patients carrying c.453-397 C allele secret more
variant ESR1 and this elevated level of variant ESR1
reduces the response to the action of estrogen, and then
risks to HBV-ALF. However, further studies are needed to
identify the robust relationship between higher level of
variant ESR1 secretion and c.453-397 T>C variation
in vivo.
Conclusions
In conclusion, our genetic epidemiological investigation
suggests that the c.453-397 T>C polymorphism is related
to the susceptibility to HBV-related liver failure and could
be part of the genetic variations which underlies the
phenotypic variation observed in individuals’ susceptibility
to HBV-ALF in Chinese population. However, our conclu-
sion need be supported by data from other populations. It
is also interesting to investigate whether the ESR1 intron
region polymorphisms are associated with alcohol and
drug induced liver failure in the west countries, where
alcohol consumption and drug use are more popular.
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